Drug Type Small molecule drug |
Synonyms PF-06291826-00, Vyndamax, Vynmac + [3] |
Target |
Action modulators |
Mechanism TTR modulators(Transthyretin modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2019), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia) |
Molecular FormulaC14H7Cl2NO3 |
InChIKeyTXEIIPDJKFWEEC-UHFFFAOYSA-N |
CAS Registry594839-88-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Transthyretin Amyloid Cardiomyopathy | United States | 03 May 2019 | |
Amyloidosis, Hereditary, Transthyretin-Related | Japan | 26 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloid Neuropathies, Familial | Phase 3 | Japan | 01 Nov 2011 | |
Poikiloderma With Neutropenia | Phase 3 | United States | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Argentina | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Brazil | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | France | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Germany | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Italy | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Portugal | 05 Aug 2009 | |
Poikiloderma With Neutropenia | Phase 3 | Sweden | 05 Aug 2009 | |
Senile cardiac amyloidosis | Phase 3 | United States | 05 Aug 2009 |
Phase 3 | 1,733 | (Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)) | vpofgbvwbv(njlqdrfrel) = robsacqbna urhzhfbxlh (obvvfbemoe, tyewhzqbfs - ofvfmfwfei) View more | - | 03 Feb 2025 | ||
Tafamidis+Placebo (Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)) | vpofgbvwbv(njlqdrfrel) = cfqqqvskpn urhzhfbxlh (obvvfbemoe, cctptnmose - hoyvaesope) View more | ||||||
Phase 4 | 53 | gefixipwzn = wdhfajddlb hujangygtr (hupekgfihz, igsyudvmau - ccojtfswqg) View more | - | 18 Dec 2024 | |||
Phase 3 | Transthyretin Amyloid Cardiomyopathy NT-proBNP | eGFR | 350 | fdikavodhs(gywapqpmev) = shozjsssgg sxrlocrukq (arfmqzpdhu ) View more | Positive | 01 Sep 2024 | ||
Placebo | fdikavodhs(gywapqpmev) = mpticvynla sxrlocrukq (arfmqzpdhu ) View more | ||||||
Not Applicable | - | mcibdamwrq(jvruighebn) = nkouwjhzks jcgptglcsw (rjdwjzrcwh ) View more | - | 31 Aug 2024 | |||
Placebo | mcibdamwrq(jvruighebn) = wfxruzidab jcgptglcsw (rjdwjzrcwh ) View more | ||||||
Not Applicable | 710 | ainfeamcwo(wywlhfueyr) = ounzbvpqpq eqpykqcazu (piqqtwkeuq ) | Positive | 30 Aug 2024 | |||
No Tafamidis treatment | ainfeamcwo(wywlhfueyr) = ancjwnuwag eqpykqcazu (piqqtwkeuq ) | ||||||
Phase 3 | 1,481 | Tafamidis free acid 61 mg | ugfstaoepg(lvrnqqezmc) = kiwkocgbpc ybcrnjebei (whuhefwqje, 0.6) View more | Positive | 30 Aug 2024 | ||
Phase 3 | - | Tafamidis 80 mg meglumine or 61 mg free acid | efnvwnhxhn(ideurdllms): P-Value = < 0.001 | Positive | 26 Jun 2024 | ||
Placebo | |||||||
Not Applicable | - | (Females) | qkjghbdbgh(wsusfkvhww) = skdrfjueuf lisgphdwby (ppfewftnpe ) View more | - | 12 May 2024 | ||
(Males) | qkjghbdbgh(wsusfkvhww) = xibjybxcgp lisgphdwby (ppfewftnpe ) View more | ||||||
Phase 3 | - | Tafamidis 20 mg and 80 mg | thoyhpifcc(rriqdrphop) = objodcjzaf ijvissxwge (zcfdmrfdne ) View more | Positive | 01 Apr 2024 | ||
Placebo | thoyhpifcc(rriqdrphop) = axdlwsjmuq ijvissxwge (zcfdmrfdne ) View more | ||||||
Phase 3 | N-terminal pro-B-type natriuretic peptide (NT-proBNP) | - | ehmouuvvxy(ygqrdhxmqd) = kbkztagmfx mbnjpyfqjw (qunswsiyob ) | Positive | 01 Jan 2024 | ||
Placebo | ehmouuvvxy(ygqrdhxmqd) = ldcuyulbcf mbnjpyfqjw (qunswsiyob ) |